Gilead said it expects total 2020 sales of $23 billion to $25 billion, up from its previous range of $21.8 billion to $22.2 billion. “We think this implies up to $1 billion to $3 billion of remdesivir, … a positive that was not expected at the start of the year,” said Jefferies analyst Michael Yee. Gilead’s second-quarter sales fell nearly 10% from a year earlier to $5.1 billion, short of the average analyst estimate of $5.3 billion, according to Refinitiv.
from Yahoo Finance https://ift.tt/3jZQACL
Leave a Reply